MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 2 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $17,459,000 | -5.1% | 1,431,058 | -0.0% | 1.10% | -36.1% |
| Q3 2020 | $18,389,000 | +26.5% | 1,431,059 | -75.0% | 1.71% | +12.5% |
| Q2 2020 | $14,540,000 | +20.5% | 5,724,235 | -3.7% | 1.52% | -25.3% |
| Q1 2020 | $12,064,000 | -6.0% | 5,942,735 | 0.0% | 2.04% | +6.6% |
| Q4 2019 | $12,836,000 | +65.3% | 5,942,735 | +17.8% | 1.91% | -4.3% |
| Q3 2019 | $7,766,000 | -62.9% | 5,042,735 | 0.0% | 2.00% | -81.2% |
| Q2 2019 | $20,927,000 | -0.7% | 5,042,735 | 0.0% | 10.63% | +26.1% |
| Q1 2019 | $21,079,000 | +45.6% | 5,042,735 | 0.0% | 8.43% | +70.4% |
| Q4 2018 | $14,473,000 | -63.6% | 5,042,735 | +26.8% | 4.95% | -45.2% |
| Q3 2018 | $39,775,000 | +41.4% | 3,977,453 | 0.0% | 9.03% | +2.4% |
| Q2 2018 | $28,121,000 | +85.1% | 3,977,453 | 0.0% | 8.81% | -1.6% |
| Q1 2018 | $15,194,000 | -53.2% | 3,977,453 | 0.0% | 8.96% | -57.9% |
| Q4 2017 | $32,456,000 | – | 3,977,453 | – | 21.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 3,977,453 | $15,194,000 | 8.96% |
| Granite Point Capital Management, L.P. | 2,638,321 | $10,078,000 | 0.98% |
| New Leaf Venture Partners, L.L.C. | 342,550 | $1,309,000 | 0.71% |
| 683 Capital Management, LLC | 1,200,000 | $4,584,000 | 0.40% |
| Virtus ETF Advisers LLC | 80,389 | $307,000 | 0.27% |
| Iguana Healthcare Management, LLC | 100,000 | $382,000 | 0.25% |
| THREE BAYS CAPITAL LP | 944,300 | $3,607,000 | 0.25% |
| Granite Point Capital Management, L.P. | 549,900 | $2,101,000 | 0.20% |
| Cormorant Asset Management, LP | 478,111 | $1,826,000 | 0.14% |
| GMT CAPITAL CORP | 2,533,798 | $9,680,000 | 0.12% |